

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI BIOLOGICS (CAYMAN) INC.

藥明生物技術有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2269)

POSITIVE PROFIT ALERT

This announcement is made by WuXi Biologics (Cayman) Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 Laws of Hong Kong).

The Company wishes to inform the shareholders (the “**Shareholders**”) and the potential investors of the Company that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group (prepared in accordance with International Financial Reporting Standards (IFRS)) for the year ended December 31, 2021, it is expected that the profit of the Company and the profit attributable to equity shareholders of the Company for the year ended December 31, 2021 will increase more than 105% and more than 98%, respectively, compared with those for the corresponding period of last year. Such increase was primarily attributable to, among other factors:

- (i) the Group’s acceleration to undertake, promptly execute and generate revenue from existing and new COVID-19 projects to support and enable the Group’s global clients in combatting against COVID-19;
- (ii) leading technology platform, best-in-industry timeline and excellent execution track record contributing to significantly higher revenue and market share of new non-COVID integrated projects;
- (iii) successful execution of “Win-the-Molecule” strategy adding considerable late-stage pipeline and near-term revenue;
- (iv) the significant manufacturing revenue growth in 2021 as the banner year for the Group’s commercial manufacturing; and

- (v) the recovery from reduced productivity due to the brief slow-down in the first quarter of 2020 as disrupted by the pandemic, coupled with the enhancement in the utilization of existing capacities and resources and the implementation of operational efficiency improvement programs leading to improved gross margin.

The Company is still in the process of finalizing the annual results of the Group for the year ended December 31, 2021. The information contained in this announcement is only based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the year ended December 31, 2021, which are subject to finalization and other potential adjustments, if any, and have not been reviewed or confirmed by the auditors of the Group or the audit committee of the board of directors of the Company. Shareholders and potential investors of the Company should refer to the annual results announcement of the Group for the year ended December 31, 2021, which is expected to be published by the end of March 2022.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
WuXi Biologics (Cayman) Inc.
Dr. Ge Li
Chairman

Hong Kong, February 7, 2022

As at the date of this announcement, the Board comprises Dr. Zhisheng Chen and Dr. Weichang Zhou as executive Directors; Dr. Ge Li, Dr. Ning Zhao, Mr. Yibing Wu and Mr. Yanling Cao as non-executive Directors; and Mr. William Robert Keller, Mr. Teh-Ming Walter Kwauk and Mr. Kenneth Walton Hitchner III as independent non-executive Directors.

* *For identification purpose only*